Kayode Ogungbenro

4.0k total citations
93 papers, 1.7k citations indexed

About

Kayode Ogungbenro is a scholar working on Statistics and Probability, Oncology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Kayode Ogungbenro has authored 93 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Statistics and Probability, 24 papers in Oncology and 19 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Kayode Ogungbenro's work include Statistical Methods in Clinical Trials (30 papers), Pharmacogenetics and Drug Metabolism (18 papers) and Drug Transport and Resistance Mechanisms (16 papers). Kayode Ogungbenro is often cited by papers focused on Statistical Methods in Clinical Trials (30 papers), Pharmacogenetics and Drug Metabolism (18 papers) and Drug Transport and Resistance Mechanisms (16 papers). Kayode Ogungbenro collaborates with scholars based in United Kingdom, United States and Switzerland. Kayode Ogungbenro's co-authors include Leon Aarons, Aleksandra Galetin, Gordon Graham, Ivelina Gueorguieva, S. Barnett, Sharon Hulme, Karelle Ménochet, Hong Shen, Amin Rostami‐Hodjegan and Andrew T. King and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Allergy and Clinical Immunology and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Kayode Ogungbenro

89 papers receiving 1.7k citations

Peers

Countries citing papers authored by Kayode Ogungbenro

Since Specialization

Citations

This map shows the geographic impact of Kayode Ogungbenro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kayode Ogungbenro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kayode Ogungbenro more than expected).

Fields of papers citing papers by Kayode Ogungbenro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kayode Ogungbenro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kayode Ogungbenro. The network helps show where Kayode Ogungbenro may publish in the future.

Co-authorship network of co-authors of Kayode Ogungbenro

This figure shows the co-authorship network connecting the top 25 collaborators of Kayode Ogungbenro. A scholar is included among the top collaborators of Kayode Ogungbenro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kayode Ogungbenro. Kayode Ogungbenro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Transporter expressions as part of required scaling factor to support in vitro in vivo extrapolation for blood-brain barrier drug permeability 2025 ·European Journal of Pharmaceutical Sciences ·Zubida M. Al‐Majdoub, Jonathan Cheong, (unknown), (unknown), Tom De Bruyn, (unknown), Jingjing Guo, Cornelis E. C. A. Hop, (unknown), Aleksandra Galetin, Kayode Ogungbenro, Amin Rostami‐Hodjegan, Jill Barber	0
2	Mathematical Modeling of Neuroinflammation in Neurodegenerative Diseases 2025 ·CPT Pharmacometrics & Systems Pharmacology ·(unknown), Amin Rostami‐Hodjegan, (unknown), Donald E. Mager, Kayode Ogungbenro	0
3	Population Pharmacokinetic Modeling of Glycochenodeoxycholic Acid 3‐O‐Sulfate ( GCDCA ‐S) as Endogenous Biomarker of OATP1B3 and OAT3 Transporters 2025 ·Clinical Pharmacology & Therapeutics ·(unknown), (unknown), Kayode Ogungbenro, Aleksandra Galetin	0
4	Population Pharmacokinetic Analysis and Simulation of Alternative Dosing Regimens for Biosimilars to Adalimumab and Etanercept in Patients with Rheumatoid Arthritis 2024 ·Pharmaceutics ·Stephanie F Ling, Kayode Ogungbenro, Adam S. Darwich, (unknown), Nisha Nair, James Bluett, Ann W Morgan, John D. Isaacs, Anthony G. Wilson, Kimme L Hyrich, Anne Barton, Darren Plant	0
5	Hierarchical cluster analysis and nonlinear mixed-effects modelling for candidate biomarker detection in preclinical models of cancer. 2024 ·European Journal of Pharmaceutical Sciences ·David Hodson, Hitesh Mistry, James Yates, (unknown), Michael Davies, Leon Aarons, Kayode Ogungbenro	3
6	Covariates in population pharmacokinetic studies of critically ill adults receiving β-lactam antimicrobials: a systematic review and narrative synthesis 2023 ·JAC-Antimicrobial Resistance ·Jan Hansel, Fahmida Mannan, Rebecca C. Robey, Mary Kumarendran, (unknown), Alexander G. Mathioudakis, Kayode Ogungbenro, Paul Dark, Timothy Felton	4
7	Exploring the Boundaries for In Vitro–In Vivo Extrapolation: Use of Isolated Rat Hepatocytes in Co-culture and Impact of Albumin Binding Properties in the Prediction of Clearance of Various Drug Types 2023 ·Drug Metabolism and Disposition ·(unknown), Kayode Ogungbenro, Tom De Bruyn, J. Brian Houston, David Hallifax	2
8	Investigation of simplified physiologically‐based pharmacokinetic models in rat and human 2023 ·CPT Pharmacometrics & Systems Pharmacology ·(unknown), Andrés Olivares‐Morales, Kayode Ogungbenro, Leon Aarons, Michael Gertz	5
9	Development of a sensitive biochemical assay for the detection of tofacitinib adherence 2023 ·Analytical Methods ·Stephanie J. Church, Kimme L Hyrich, Kayode Ogungbenro, Richard D. Unwin, Anne Barton, James Bluett	2
10	Radiation in Combination with Immune Checkpoint Blockade and DNA Damage Response Inhibitors in Mice: Dosage Optimization in MC38 Syngeneic Tumors via Modelling and Simulation 2023 ·Journal of Pharmacology and Experimental Therapeutics ·David Hodson, Hitesh Mistry, James Yates, Paul Farrington, Anna D. Staniszewska, (unknown), Michael Davies, Leon Aarons, Kayode Ogungbenro	2
11	In Vitro to In Vivo Extrapolation Linked to Physiologically Based Pharmacokinetic Models for Assessing the Brain Drug Disposition 2022 ·The AAPS Journal ·(unknown), Sibylle Neuhoff, Amin Rostami‐Hodjegan, Hiroyuki Takita, Zubida M. Al‐Majdoub, Kayode Ogungbenro	16
12	Model-Informed Precision Dosing: Background, Requirements, Validation, Implementation, and Forward Trajectory of Individualizing Drug Therapy 2020 ·The Annual Review of Pharmacology and Toxicology ·Adam S. Darwich, Thomas M. Polasek, Jeffrey K Aronson, Kayode Ogungbenro, Daniel F. B. Wright, Brahim Achour, Jean‐Luc Reny, Youssef Daali, Birgit Eiermann, Jack Cook, Lawrence J. Lesko, Andrew J. McLachlan, Amin Rostami‐Hodjegan	109
13	Population Pharmacokinetics of Teicoplanin in Preterm and Term Neonates: Is It Time for a New Dosing Regimen? 2020 ·Antimicrobial Agents and Chemotherapy ·(unknown), Kosmas Sarafidis, Olga Begou, Helen Gika, (unknown), Kayode Ogungbenro, Aristides Dokoumetzidis, Eleni Agakidou, Emmanuel Roilides	12
14	A population pharmacokinetic model for simvastatin and its metabolites in children and adolescents 2019 ·European Journal of Clinical Pharmacology ·Kayode Ogungbenro, Jonathan B. Wagner, Susan M. Abdel‐Rahman, J. Steven Leeder, Aleksandra Galetin	4
15	Predicting survival of pancreatic cancer patients treated with gemcitabine using longitudinal tumour size data 2016 ·Cancer Chemotherapy and Pharmacology ·(unknown), Hitesh Mistry, Kayode Ogungbenro, Leon Aarons	8
16	A HPLC-SRM-MS based method for the detection of adherence to low-dose oral methotrexate 2015 ·Arthritis & Rheumatism ·James Bluett, (unknown), Kayode Ogungbenro, Isabel Riba‐Garcia, Richard D. Unwin, Suzanne Verstappen, Anne Barton	1
17	Reduction of a Whole-Body Physiologically Based Pharmacokinetic Model to Stabilise the Bayesian Analysis of Clinical Data 2015 ·The AAPS Journal ·(unknown), Nikolaos Tsamandouras, (unknown), Etienne Pigeolet, Kayode Ogungbenro, Leon Aarons	18
18	Model-Based Evaluation of the Impact of Formulation and Food Intake on the Complex Oral Absorption of Mavoglurant in Healthy Subjects 2014 ·Pharmaceutical Research ·(unknown), Kayode Ogungbenro, Etienne Pigeolet, (unknown), Ralph Woessner, Leon Aarons	16
19	A Physiologically Based Pharmacokinetic Model for Clobazam and Stiripentol in Adults and Children 2014 ·Pharmaceutical Research ·(unknown), Kayode Ogungbenro, Leon Aarons	9
20	The use of a modified Fedorov exchange algorithm to optimise sampling times for population pharmacokinetic experiments 2005 ·Computer Methods and Programs in Biomedicine ·Kayode Ogungbenro, Gordon Graham, Ivelina Gueorguieva, Leon Aarons	27

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact